Aptorum Group Limited

APM

KYG6096M1226

Pharmaceuticals

Delayed Nasdaq Other stock markets 02:25:02 2024-05-15 pm EDT			5-day change	1st Jan Change
4.723 ^USD	+2.68%		+4.96%	+92.90%

Apr. 30	Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Top Midday Gainers	MT

Aptorum Group Limited Appoints Ian Huen as Director

December 03, 2021 at 08:01 am EST

On December 2, 2021, Aptorum Group Limited held its 2021 annual general meeting of shareholders, approved the appointment of Mr. Ian Huen as Director.

Latest news about Aptorum Group Limited

Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Top Midday Gainers	Mar. 06	MT
YOOV Group Holding Limited entered into a entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited for $250 million in a reverse merger transaction.	Mar. 05	CI
Top Premarket Decliners	Jan. 29	MT
Aptorum Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	Dec. 22	CI
Aptorum Group Limited Announces Chief Executive Changes	Nov. 30	CI
Aptorum Group Limited Announces Management Changes	Nov. 30	CI
Aptorum Group Limited announced that it has received $3 million in funding from Jurchen Investment Corporation	23-09-10	CI
Top Premarket Decliners	23-08-28	MT
Aptorum Group Obtains Nasdaq Authorization to Transfer Listing to Nasdaq Capital Market	23-08-10	MT
Top Premarket Gainers	23-07-18	MT
Aptorum Group Limited Announces Resignation of Thomas Lee as Head of Research and Development	23-06-30	CI
Aptorum Group Limited announced that it has received $3 million in funding	23-06-27	CI
Aptorum Group Limited Provides Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma	23-06-22	CI
Biopharmaceutical Group Aptorum to Delist from Euronext Paris	23-06-12	MT
Top Premarket Decliners	23-05-18	MT
Top Midday Decliners	23-05-08	MT
Looming Economic Data Prompt Quiet Premarket Action for US Equity Futures	23-05-08	MT
Top Premarket Decliners	23-05-08	MT
Aptorum Group Gets Non-Compliance Notice From Nasdaq -- Shares Slump in Premarket	23-05-08	MT
Aptorum Group Gets Non-Compliance Notice From Nasdaq	23-05-08	MT
Top Premarket Gainers	23-05-03	MT
Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Aptorum, URF Holding Group to Combine in Reverse Takeover	23-03-27	MT
URF Holding Group Limited entered into a non-binding Letter of Intent and Term Sheet to acquire Aptorum Group Limited for $40 million in a reverse merger transaction.	23-03-26	CI

Aptorum Group Limited is United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Companyâs lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.

Sector

Pharmaceuticals

Calendar

2024-09-09 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
APTORUM GROUP LIMITED	+92.90%	25.17M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.81%	364B
MERCK & CO., INC.	+20.37%	326B
ABBVIE INC.	+5.47%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.87%	167B
PFIZER, INC.	+0.12%	161B

Other Pharmaceuticals